PK study approval for VAL001
Respiratorius announces that the PK study is now approved by the Health Authorities (HA) in the country for the PK study conduct. The study has previously been approved by the Ethics Committee (EC) but the recent minor changes requested by the HA need to be reviewed and re-approved by the EC before the study can be initiated. Thereafter the study can be initiated, and study subjects can be recruited as soon as possible.The patent pending novel formulation, VAL001, combines immediate release and extended-release characteristics of sodium valproate contained in a capsule formulation. This